Seres Therapeutics, Inc. (MCRB) stock
MCRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.41+0.00 (0.00%)
Close on Nov 17, 2026Market cap $14.02MP/E –Yield –
Seres Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Seres Therapeutics's operating margin for the twelve months ending Jun 30, 2026 was -4462.8%. For fiscal 2025 it was -11910.1%, against -2524.0% the year before. The highest annual figure on record is -44.5% in fiscal 2021.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -11910.1% | −9386.1 |
| FY2022 | Dec 31, 2022 | -2524.0% | −2479.5 |
| FY2021 | Dec 31, 2021 | -44.5% | +220.8 |
| FY2020 | Dec 31, 2020 | -265.3% | −57.0 |
| FY2019 | Dec 31, 2019 | -208.3% | +146.5 |
| FY2018 | Dec 31, 2018 | -354.8% | −70.1 |
| FY2017 | Dec 31, 2017 | -284.7% | +141.8 |
| FY2016 | Dec 31, 2016 | -426.5% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -2890.4% | +54959.6 |
| Q1 FY2026 | Mar 31, 2026 | -5839.9% | +8542.6 |
| Q4 FY2025 | Dec 31, 2025 | -4424.0% | −4463.1 |
| Q3 FY2025 | Sep 30, 2025 | -6403.7% | −6226.2 |
| Q4 FY2023 | Dec 31, 2023 | -57850.0% | −56133.8 |
| Q3 FY2023 | Sep 30, 2023 | -14382.6% | −9174.9 |
| Q2 FY2023 | Jun 30, 2023 | 39.2% | +3773.3 |
| Q4 FY2022 | Dec 31, 2022 | -177.5% | +507.0 |
| Q3 FY2022 | Sep 30, 2022 | -1716.2% | −1770.2 |
| Q2 FY2022 | Jun 30, 2022 | -5207.6% | −4292.9 |
| Q1 FY2022 | Mar 31, 2022 | -3734.2% | −3116.4 |
| Q4 FY2021 | Dec 31, 2021 | -684.6% | −582.7 |
| Q3 FY2021 | Sep 30, 2021 | 54.0% | +2170.8 |
| Q2 FY2021 | Jun 30, 2021 | -914.7% | −574.9 |
| Q1 FY2021 | Mar 31, 2021 | -617.8% | −377.3 |
| Q4 FY2020 | Dec 31, 2020 | -101.9% | +149.9 |
| Q3 FY2020 | Sep 30, 2020 | -2116.8% | −1872.4 |
| Q2 FY2020 | Jun 30, 2020 | -339.9% | −252.5 |
| Q1 FY2020 | Mar 31, 2020 | -240.5% | +94.9 |
| Q4 FY2019 | Dec 31, 2019 | -251.8% | −47.9 |
| Q3 FY2019 | Sep 30, 2019 | -244.4% | +0.9 |
| Q2 FY2019 | Jun 30, 2019 | -87.4% | +522.7 |
| Q1 FY2019 | Mar 31, 2019 | -335.4% | +376.4 |
| Q4 FY2018 | Dec 31, 2018 | -203.9% | +770.4 |
| Q3 FY2018 | Sep 30, 2018 | -245.3% | −213.5 |
| Q2 FY2018 | Jun 30, 2018 | -610.1% | +332.7 |
| Q1 FY2018 | Mar 31, 2018 | -711.8% | +146.9 |
| Q4 FY2017 | Dec 31, 2017 | -974.3% | −128.2 |
| Q3 FY2017 | Sep 30, 2017 | -31.8% | +114.9 |
| Q2 FY2017 | Jun 30, 2017 | -942.8% | – |
| Q1 FY2017 | Mar 31, 2017 | -858.7% | – |
| Q4 FY2016 | Dec 31, 2016 | -846.1% | – |
| Q3 FY2016 | Sep 30, 2016 | -146.7% | – |
See a number that looks wrong?